PRA
JUNO

Parametric Risk Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Parametric Risk Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-65,000
Closed -$2.86M – 151
2015
Q4 		$2.86M Buy
+65,000
New +$3.22M 0.2% 62

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Parametric Risk Advisors's JUNO Position: Q1 2016 in Review

Parametric Risk Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 65,000 shares — an estimated $2.86M sold.

Parametric Risk Advisors first reported a position in JUNO in Q4 2015 and held it in 1 quarter. The position peaked at $2.86M in Q4 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

  • Parametric Risk Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Parametric Risk Advisors sold 65,000 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $2.86M.
  • Parametric Risk Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Parametric Risk Advisors's Juno Therapeutics, Inc. position peaked at $2.86M in Q4 2015.
  • 158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on Parametric Risk Advisors's 13F filing for Q1 2016, filed 13 May 2016.